LY9 and Miyoshi myopathy: Furthermore, MM patients bearing elevated CD229 expression suffered from poor prognosis in both newly diagnosed MM from TT2 (Total Therapy 2) cohort (p < 0.01) (Figure 1E) and relapsed MM patients from APEX (Assessment of Proteasome inhibition for Extending remissions) cohort (p < 0.01) (Figure 1F).